1
Country: China | Funding: $370M
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
2
Country: UK | Funding: $414M
Artios develops a pipeline of DNA damage response (DDR)-targeting cancer prospects, that is based on the idea that tumor cells use DDR pathways to manage DNA damage. By inhibiting key components of the DDR, a DDR inhibitor can kill cancerous cells while skipping healthy ones. Company's lead candidate, alnodesertib (DNA polymerase theta inhibitor) is intenede to treat pancreatic cancer, breast and third-line colorectal cancer. It has demonstrated durable responses in patients with eight different solid tumor types whose tumors had ATM deficiency. Artios’ pipeline also features a DDR inhibitor antibody-drug conjugate (DDR-ADC) discovery program
Artios develops a pipeline of DNA damage response (DDR)-targeting cancer prospects, that is based on the idea that tumor cells use DDR pathways to manage DNA damage. By inhibiting key components of the DDR, a DDR inhibitor can kill cancerous cells while skipping healthy ones. Company's lead candidate, alnodesertib (DNA polymerase theta inhibitor) is intenede to treat pancreatic cancer, breast and third-line colorectal cancer. It has demonstrated durable responses in patients with eight different solid tumor types whose tumors had ATM deficiency. Artios’ pipeline also features a DDR inhibitor antibody-drug conjugate (DDR-ADC) discovery program
3
Country: USA | Funding: $280.8M
Triana Biomedicines is developing a platform to discover molecular "glues" for disease regulation. This technology identifies small molecules that facilitate interactions between two proteins (work like a glue). One such application aims to activate the innate protein degradation pathway to destroy disease-specific protein (for example in cancer cells). The company's lead candidate, TRI-611, a molecular degrader targeting ALK-positive anaplastic lymphoma kinase, is aimed at treating non-small cell lung cancer (NSCLC) and is capable of overcoming resistance observed with existing treatments. The company also has clinical trials in breast cancer in its pipeline. Pfizer is a major investor.
Triana Biomedicines is developing a platform to discover molecular "glues" for disease regulation. This technology identifies small molecules that facilitate interactions between two proteins (work like a glue). One such application aims to activate the innate protein degradation pathway to destroy disease-specific protein (for example in cancer cells). The company's lead candidate, TRI-611, a molecular degrader targeting ALK-positive anaplastic lymphoma kinase, is aimed at treating non-small cell lung cancer (NSCLC) and is capable of overcoming resistance observed with existing treatments. The company also has clinical trials in breast cancer in its pipeline. Pfizer is a major investor.
4
Country: Germany | Funding: $2B
BioNTech is a global leader in mRNA-based immunotherapy. The company was the first to invent and commercialize a COVID-19 vaccine (in partnership with Pfizer). BioNTech is currently developing several personalized immunotherapeutic agents (vaccines) against cancer and infectious diseases, including melanoma, human papillomavirus, non-small cell lung cancer, tuberculosis and malaria. The company's flagship platform, FixVac, enables the creation of ready-to-use mRNA cancer vaccines that can be used off-shelf to a specific indication (fixed-dose vaccines). These vaccines are a fixed combination of unmutated tumor antigens encoded by mRNA, which are frequently expressed in certain types of cancer. The mRNA is delivered using a proprietary RNA-lipoplex delivery system, which is designed to enhance mRNA stability in the body and target antigen-presenting dendritic cells (DCs), the training grounds of our immune system.
BioNTech is a global leader in mRNA-based immunotherapy. The company was the first to invent and commercialize a COVID-19 vaccine (in partnership with Pfizer). BioNTech is currently developing several personalized immunotherapeutic agents (vaccines) against cancer and infectious diseases, including melanoma, human papillomavirus, non-small cell lung cancer, tuberculosis and malaria. The company's flagship platform, FixVac, enables the creation of ready-to-use mRNA cancer vaccines that can be used off-shelf to a specific indication (fixed-dose vaccines). These vaccines are a fixed combination of unmutated tumor antigens encoded by mRNA, which are frequently expressed in certain types of cancer. The mRNA is delivered using a proprietary RNA-lipoplex delivery system, which is designed to enhance mRNA stability in the body and target antigen-presenting dendritic cells (DCs), the training grounds of our immune system.
5
Country: USA | Funding: $256M
Acepodia is a therapeutics company that employs flexible therapeutic design to treat cancer.
Acepodia is a therapeutics company that employs flexible therapeutic design to treat cancer.
6
Country: USA | Funding: $220M
Paige.AI was one of the first startups to apply AI models to cancer care and has since developed numerous models used for tissue analysis, tissue subtyping and molecular biomarker discovery. Paige has developed several AI applications for diagnostic decision support in oncology pathology, including prostate cancer detection and diagnosis in whole-section prostate biopsy images, identifying and classifying breast cancer in whole-section biopsy and excisional breast specimens, detecting and classifying benign and malignant diseases throughout the gastrointestinal tract. Developed using Virchow and trained on over 1.5 million slides, the Paige PanCancer Suite helps pathologists identify the subtlest nuances of cancer progression in various tissue types, including rare cancers. Acquired by Tempus
Paige.AI was one of the first startups to apply AI models to cancer care and has since developed numerous models used for tissue analysis, tissue subtyping and molecular biomarker discovery. Paige has developed several AI applications for diagnostic decision support in oncology pathology, including prostate cancer detection and diagnosis in whole-section prostate biopsy images, identifying and classifying breast cancer in whole-section biopsy and excisional breast specimens, detecting and classifying benign and malignant diseases throughout the gastrointestinal tract. Developed using Virchow and trained on over 1.5 million slides, the Paige PanCancer Suite helps pathologists identify the subtlest nuances of cancer progression in various tissue types, including rare cancers. Acquired by Tempus
7
Country: USA | Funding: $208.3M
Halda is developing RIPTAC - a new class of precision anti-cancer drugs. RIPTAC technology binds two proteins: one specific to the tumor and one that performs an essential function. This protein-protein interaction enables to selective destruct cancer cells. Halda's portfolio includes oral therapeutic drugs for treatment of metastatic castration-resistant prostate cancer and breast cancer. Clinical trials have already demonstrated good tolerability of this new therapy and encouraging signs of anti-tumor activity, including reductions in prostate-specific antigen (PSA) levels and Response Evaluation Criteria in Solid Tumors (RECIST) responses in patients with advanced prostate cancer, many of whom have progressed after several prior therapies and exhausted available treatment options. Acquired by Johnson & Johnson
Halda is developing RIPTAC - a new class of precision anti-cancer drugs. RIPTAC technology binds two proteins: one specific to the tumor and one that performs an essential function. This protein-protein interaction enables to selective destruct cancer cells. Halda's portfolio includes oral therapeutic drugs for treatment of metastatic castration-resistant prostate cancer and breast cancer. Clinical trials have already demonstrated good tolerability of this new therapy and encouraging signs of anti-tumor activity, including reductions in prostate-specific antigen (PSA) levels and Response Evaluation Criteria in Solid Tumors (RECIST) responses in patients with advanced prostate cancer, many of whom have progressed after several prior therapies and exhausted available treatment options. Acquired by Johnson & Johnson
8
Country: USA | Funding: $187M
Callio Therapeutics develops next-generation, multi-payload antibody-drug conjugates (ADCs).
Callio Therapeutics develops next-generation, multi-payload antibody-drug conjugates (ADCs).
9
Country: Canada | Funding: $120.1M
Oncolytics Biotech is developing REOLYSIN®, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.
Oncolytics Biotech is developing REOLYSIN®, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.
10
Country: USA | Funding: $112.3M
iMDx is focused on cancers with large patient populations and significant unmet need. The company is developing three genetic tests – blood tests for breast cancer and lung cancer, and a urine-based test for bladder cancer.
iMDx is focused on cancers with large patient populations and significant unmet need. The company is developing three genetic tests – blood tests for breast cancer and lung cancer, and a urine-based test for bladder cancer.
11
Country: USA | Funding: $106M
Totus Medicines is a provider of chemical biology technologies by creating life-changing covalent drugs.
Totus Medicines is a provider of chemical biology technologies by creating life-changing covalent drugs.
12
Country: USA | Funding: $95M
Osiris Therapeutics is a stem cell company, which focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound healing markets. The company operates its business through two segments: Therapeutics and Biosurgery segment. The Therapeutics segment focuses on developing biologic stem cell drug candidates from readily available and non-controversial sources. One of its products, Stromagen was used to treat breast cancer in clinical trials.
Osiris Therapeutics is a stem cell company, which focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound healing markets. The company operates its business through two segments: Therapeutics and Biosurgery segment. The Therapeutics segment focuses on developing biologic stem cell drug candidates from readily available and non-controversial sources. One of its products, Stromagen was used to treat breast cancer in clinical trials.
13
Country: Israel | Funding: $72M
Ayala Pharmaceuticals develops a personalized treatment for cancer.
Ayala Pharmaceuticals develops a personalized treatment for cancer.
14
Country: Switzerland | Funding: $65.7M
NBE-Therapeutics develops ADCs for the treatment of solid tumors (in particular breast and pancreatic cancers). Its platform enables to develop targeted therapies that have a long-lasting immunological effect and can shrink or even completely eradicate tumors. The company has a portfolio of ADC candidates based on proprietary linker loading and conjugation technologies, which are at various stages of pipeline. The company's technologies enable to find the optimal combination of properties for each target antigen: enzymatic conjugation with the enzyme sortase A, SMAC technology (sortase-mediated antibody conjugation), a highly potent anthracycline-based intercalating toxin that damages DNA (as a payload), novel binding agents for finding any new targets and a mammalian antibody library display system. The company is financially backed by the Boehringer Ingelheim Venture Fund.
NBE-Therapeutics develops ADCs for the treatment of solid tumors (in particular breast and pancreatic cancers). Its platform enables to develop targeted therapies that have a long-lasting immunological effect and can shrink or even completely eradicate tumors. The company has a portfolio of ADC candidates based on proprietary linker loading and conjugation technologies, which are at various stages of pipeline. The company's technologies enable to find the optimal combination of properties for each target antigen: enzymatic conjugation with the enzyme sortase A, SMAC technology (sortase-mediated antibody conjugation), a highly potent anthracycline-based intercalating toxin that damages DNA (as a payload), novel binding agents for finding any new targets and a mammalian antibody library display system. The company is financially backed by the Boehringer Ingelheim Venture Fund.
15
Country: UK | Funding: $39.8M
Around the world the incidence of cancer is growing, and with it the demand for better, faster and less expensive solutions for diagnosis and treatment. With the aim of bringing cancer care to everyone, everywhere, Endomag is developing a clinical platform that uses safe magnetic fields to power diagnostic and therapeutic devices, avoiding the safety, workflow and availability concerns of ionizing radiation.
Around the world the incidence of cancer is growing, and with it the demand for better, faster and less expensive solutions for diagnosis and treatment. With the aim of bringing cancer care to everyone, everywhere, Endomag is developing a clinical platform that uses safe magnetic fields to power diagnostic and therapeutic devices, avoiding the safety, workflow and availability concerns of ionizing radiation.
16
Country: USA | Funding: $34.3M
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
17
Country: UK | Funding: $22m
Kheiron Medical Technologies aims to help radiologists detect breast cancer earlier by using deep learning
Kheiron Medical Technologies aims to help radiologists detect breast cancer earlier by using deep learning
18
Country: South Korea | Funding: ₩27B
Aston Sci is a clinical-stage biopharmaceutical company that develops medicines in oncology, immunology, and geriatrics. It's cancer vaccine is being evaluated for breast and gastric cancer
Aston Sci is a clinical-stage biopharmaceutical company that develops medicines in oncology, immunology, and geriatrics. It's cancer vaccine is being evaluated for breast and gastric cancer
19
Country: USA | Funding: $18.8M
4D Path uses H&E biopsy images to unveil hidden data instantly providing biomarker profiling and stratification. Although their initial focus is on breast cancer, the company is actively working on developing products for ovarian cancer, cervical cytology, skin cancer, and, in general, around immunotherapy in various cancers.
4D Path uses H&E biopsy images to unveil hidden data instantly providing biomarker profiling and stratification. Although their initial focus is on breast cancer, the company is actively working on developing products for ovarian cancer, cervical cytology, skin cancer, and, in general, around immunotherapy in various cancers.
20
Country: Australia | Funding: $17.1M
OncoRes Medical develops an imaging technology to provide intraoperative information available to breast cancer surgeons.
OncoRes Medical develops an imaging technology to provide intraoperative information available to breast cancer surgeons.
